Oct 17, 2022 / 07:30PM GMT
Unidentified Participant
Hello, everyone. Welcome to the H.C. Wainwright Sixth Annual NASH Conference. For our next presentation, we have Dr. Ben Bruno, Director of Clinical Development of Lipocine Pharmaceuticals, a clinical-stage company focused on metabolic and endocrine disorders.
Thank you very much for joining us. Dr. Bruno, please go ahead.
Ben Bruno - Lipocine Inc. - Director of Clinical Development
Thanks, Thomas, and thanks to the organizers for this opportunity to present our exciting results from our couple of NASH studies. First, our forward-looking statements. And before I get into the NASH study results, I just wanted to take a second to introduce with the scene as a whole. We are generally looking to use our validated drug-delivery technology to use steroids or steroid-related molecules to treat a number of diseases.
We've got active clinical programs to treat postpartum depression in women with epilepsy. We also have a companion liver disease project to this NASH project that as a trial currently enrolling men on a liver transplant
Lipocine Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers